QUEBEC SHOWS LEADERSHIP IN SUPPORTING PEOPLE WITH OSTEOPOROSIS
TORONTO, Feb. 1 /CNW/ - Today Quebec is providing access to a therapy in
a new class of osteoporosis treatments. With Quebec being the first
province to list Prolia® (denosumab) on public and private drug plans,
Canadians living with osteoporosis in the province of Quebec now have
access to increased treatment options.
"Canadians living with osteoporosis deserve access to all proven
treatments for the disease," said Dr. Famida Jiwa, President & CEO,
Osteoporosis Canada. "Osteoporosis Canada urges all Canadian provinces
and territories to follow Quebec's lead, and provide patients access to
all approved therapeutic options. Osteoporosis Canada continues to work with officials in each province
and territory to ensure that all patients with osteoporosis have
options and access to the medications they need."
Despite the positive news in Quebec, patient access to osteoporosis
treatments in Canada is limited and varies across the country. In
addition, some patients have difficulty tolerating currently available
"The Quebec listing of Prolia on drug plans is good news for individuals
with osteoporosis since it will ultimately support physicians to better
treat this debilitating disease," said Dr. Jacques Brown, Member, Osteoporosis Canada Scientific Advisory Council.
"The devastating health consequences caused by osteoporosis can be
prevented with effective treatments. That is why it is critically
important to have access to effective medications to treat osteoporosis
no matter the province where you live."
All women in Quebec covered by the provincial drug plan or by private
drug plans now have access to Prolia (denosumab), a new treatment for
postmenopausal women with osteoporosis at high risk for fracture.
Prolia is listed as a médicament d'exception for the treatment of women with postmenopausal osteoporosis who cannot
take an oral bisphosphonate due to a serious intolerance or
"All we want is for patients with osteoporosis to have access to a range of
treatment options to help prevent broken bones. More treatment options
mean that doctors can pick from a variety of drugs to treat
osteoporosis," said Larry Funnell, Chair, Canadian Osteoporosis Patient
Network (COPN). "Having Prolia available on public and private drugs
plans in Quebec means almost half a million women with osteoporosis
will gain access to a new treatment option so they can hopefully live
better with this disease."
Osteoporosis could strike you or someone you love. It is a silent
disease that affects nearly two million Canadians. A 50-year-old woman
has a 40% chance of developing hip, vertebral or wrist fractures during
her lifetime. Yet, despite the high prevalence of fractures, they are
not appropriately assessed or treated, leaving osteoporosis undiagnosed
and undertreated. These fractures have devastating health consequences
including pain, decreased quality of life, loss of independence and
even death. Preventing new fractures for those who have already had an
osteoporotic fracture is Osteoporosis Canada's top priority.
Osteoporosis Canada's new guidelines help physicians and patients
better identify the risk of fracture, resulting in better fracture
prevention and better management for Canadians that suffer from
Some additional osteoporosis statistics:
One in four women and one in eight men over 50 have osteoporosis.
Less than 40% of fracture patients in Canada currently undergo
investigation or adequate treatment for osteoporosis.
At least 80% of fractures in people 60+ are related to osteoporosis.
Osteoporosis causes 70-90% of the 30,000 hip fractures than occur in
Canada each year.
Of the patients who fracture a hip, 23% die within the next year.
The one in six lifetime risk of hip fracture is greater than the one in
nine lifetime risk of developing breast cancer.
One in four women who have a new vertebral fracture will fracture again
within one year.
About Osteoporosis Canada
Osteoporosis Canada, a registered charity, is the only national
organization serving people who have or are at risk for osteoporosis.
In keeping with our vision of a Canada without osteoporotic fractures,
the organization works to educate, empower and support individuals and
communities in the risk-reduction and treatment of osteoporosis by
providing medically accurate information to patients, health
professionals and the public. For more information, visit www.osteoporosis.ca.
SOURCE Osteoporosis Canada
For further information:
or to arrange an interview with an Osteoporosis Canada spokesperson, please contact: